OK11 Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.91 |
| 52 Week High | US$1.47 |
| 52 Week Low | US$0.76 |
| Beta | -3.36 |
| 11 Month Change | -7.65% |
| 3 Month Change | -4.74% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| OK11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.1% | -1.1% | 1.1% |
| 1Y | n/a | -18.8% | 7.2% |
Return vs Industry: Insufficient data to determine how OK11 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how OK11 performed against the German Market.
Price Volatility
| OK11 volatility | |
|---|---|
| OK11 Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OK11's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OK11's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3 | Gary Jacob | okyopharma.com |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain.
OKYO Pharma Limited Fundamentals Summary
| OK11 fundamental statistics | |
|---|---|
| Market cap | €33.63m |
| Earnings (TTM) | -€15.93m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs OK11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OK11 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$7.51m |
| Gross Profit | -US$7.51m |
| Other Expenses | US$9.32m |
| Earnings | -US$16.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OK11 perform over the long term?
See historical performance and comparison